In the first randomized HRMM study reported to date, the addition of elotuzumab to RVd induction and maintenance did not improve patient outcomes. However, the PFS and OS seen in both arms of the study exceeded the original statistical assumptions and support the role for PI/IMiD combination maintenance therapy for this patient population. The S1211 data will serve as an important benchmark for future HRMM clinical trials. Clinical trial information: NCT01668719
The Video Journal of Hematological Oncology (VJHemOnc): Suzanne Lentzsch, MD, PhD, Columbia University, New York, NY, USA, takes you through a selection of the most important studies presented at ASCO 2020 in multiple myeloma:
ASCO 2020 | Highlights in multiple myeloma at ASCO 2020
Poster Discussion Session
ASCO Direct™ Focus – ASCO®20 Virtual Program
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Hematologic Malignancies (Abstracts #LBA3, 8500, 8502)
Access Content Now